Pediatric Combo Drugs Could Rely On Individual Active Ingredient Studies
FDA may allow sponsors of combination drugs to rely on data from studies of individual drug components for pediatric submissions.
FDA may allow sponsors of combination drugs to rely on data from studies of individual drug components for pediatric submissions.